Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
Medtronic
AstraZeneca
McKesson

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR INSULIN GLULISINE RECOMBINANT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Insulin Glulisine Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00115570 ↗ Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents Completed Sanofi Phase 3 2005-04-01 The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
NCT00135057 ↗ Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin Completed Sanofi Phase 3 2004-04-01 The purpose of this study is to compare the change in glycemic control, as measured by hemoglobin A1c (HbA1c) from baseline to study week 24, in subjects receiving insulin glulisine as mealtime insulin following a variable bolus insulin regimen (based on carbohydrate counting) versus a fixed bolus insulin regimen, with insulin glargine as basal insulin in both arms of the study.
NCT00135083 ↗ Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus Completed Sanofi Phase 3 2004-08-01 The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.
NCT00135096 ↗ Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin Completed Sanofi Phase 3 2004-08-01 The purpose of this study is to compare the change in weight from baseline to study week 52 in the per-protocol population of pre-meal insulin glulisine (Apidra) versus post-meal Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.
NCT00135941 ↗ Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Completed Sanofi Phase 3 2005-08-01 The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI versus treatment with premix insulin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Glulisine Recombinant

Condition Name

Condition Name for Insulin Glulisine Recombinant
Intervention Trials
Diabetes Mellitus, Type 2 19
Diabetes Mellitus, Type 1 15
Type 2 Diabetes 10
Diabetes Mellitus 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Glulisine Recombinant
Intervention Trials
Diabetes Mellitus 69
Diabetes Mellitus, Type 2 37
Diabetes Mellitus, Type 1 28
Hyperglycemia 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Glulisine Recombinant

Trials by Country

Trials by Country for Insulin Glulisine Recombinant
Location Trials
United States 128
Germany 11
Poland 8
United Kingdom 7
Russian Federation 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Glulisine Recombinant
Location Trials
Georgia 10
California 9
Minnesota 8
Florida 8
New Jersey 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Glulisine Recombinant

Clinical Trial Phase

Clinical Trial Phase for Insulin Glulisine Recombinant
Clinical Trial Phase Trials
Phase 4 44
Phase 3 24
Phase 2 5
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Glulisine Recombinant
Clinical Trial Phase Trials
Completed 74
Terminated 7
Unknown status 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Glulisine Recombinant

Sponsor Name

Sponsor Name for Insulin Glulisine Recombinant
Sponsor Trials
Sanofi 59
Emory University 6
Medical University of Warsaw 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Glulisine Recombinant
Sponsor Trials
Industry 79
Other 56
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Dow
Johnson and Johnson
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.